Biogen to buy Apellis Pharmaceuticals for $5.6 billion
31/03/2026 12:02
March 31 (Reuters) - Biogen BIIB.O said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash. (Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout